The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•16 April 2026•

1 min read

Precision BioSciences Receives Approval to Expand Hepatitis B Clinical Trials in Europe

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Precision BioSciences received Clinical Trial Application (CTA) approval to expand its ELIMINATE-B clinical trial into France and Spain.

Precision BioSciences (Nasdaq: DTIL) has received Clinical Trial Application (CTA) approval to expand its ELIMINATE-B clinical trial into France and Spain. This expansion aims to accelerate the global clinical development of PBGENE-HBV, a candidate targeting chronic hepatitis B. The company utilizes its proprietary ARCUS platform to develop advanced in vivo gene editing therapies. Expanding into major European markets represents a significant operational milestone for the biotech firm, providing access to a broader patient demographic. This regulatory progress is an incremental but positive step in the company's long-term clinical strategy. The move underscores the growing global footprint of Precision BioSciences in the competitive gene-editing landscape.